Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04526899 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment
A Phase 2 study of Unresectable Melanoma and Melanoma Stage IV, sponsored by BioNTech SE.
- Completed
- Registry status
- Phase 2
- Development phase
- 184
- Enrollment target
- 20
- Study locations
NCT04526899: Completed Phase 2 study of Unresectable Melanoma and Melanoma Stage IV, sponsored by BioNTech SE.
NCT04526899 is a Phase 2 study of Unresectable Melanoma and Melanoma Stage IV that has completed, run by BioNTech SE. The registered enrollment target is 184 participants, above the 134-participant average among 24 other Unresectable Melanoma trials with a reported enrollment target (37% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04526899, a Phase 2 study of Unresectable Melanoma and Melanoma Stage IV, has completed, sponsored by BioNTech SE.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 184 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label, randomized, multi-site, Phase II, interventional trial designed to evaluate the efficacy, tolerability, and safety of BNT111 + cemiplimab in anti-programmed death protein 1 (PD-1)/anti-programmed death ligand 1 (PD-L1)-refractory/relapsed patients with unresectable Stage III or IV melanoma. The contributions of BNT111 and cemiplimab will be delineated in single agent calibrator arms. Patients will be randomized in a 2:1:1 ratio to Arm 1 (BNT111 + cemiplimab) and calibrator Arm 2 (BNT111 monotherapy), and Arm 3 (cemiplimab monotherapy). Patients in single agent calibrator arms (Arms 2 and 3), who experience centrally verified disease progression under single agent treatment, may be offered addition of the other compound to the ongoing treatment after re-consent.
Primary Outcome
ORR was defined as the percentage of participants in whom a complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumors version 1.1 (RECIST v1.1) was observed as best overall response by blinded independent central review (BICR). Per RECIST 1.1 criteria, CR defined as the disappearance of all target lesions and PR was defined as the \>=30% decrease in the sum of the longest diameter of target lesions.
Conditions Studied
Interventions
- BIOLOGICAL Cemiplimab
- BIOLOGICAL BNT111
Study Locations (20)
Other
- Border Medical Oncology - East Albury
- Gold Coast Hospital - Southport
- Melanoma Institute Australia - Sydney
- Klinik für Dermatologie, Dermatochirurgie, Allergologie, Klinikum Bremen-Ost, Gesundheitnord GmbH - Bremen
- Universitätsklinikum Essen (AoR) - Essen
- Universitätsklinikum Freiburg, Klinik füer Dermatologie und Venerologie - Freiburg im Breisgau
- Universitätsklinikum Heidelberg - Heidelberg
- Universitätsklinikum Schleswig-Holstein (UKSH), Campus Kiel Hautkrebszentrum Kiel - Kiel
- Universitätsklinikum Leipzig - Leipzig
- Universitätsmedizin der Johannes Gutenberg Universität Mainz KoeR - Mainz
- Universitätsklinikum Mannheim GmbH - Mannheim
- Klinikum Nürnberg Nord - Nuremberg
- University Hospital Tübingen - Tübingen
- Klinikum der Julius-Maximilians-Universität Würzburg - Würzburg
Arizona
- University Of Arizona College Of Medicine - Tucson
California
- University of California, San Francisco: Helen Diller Family Comprehensive Cancer Center - San Francisco
Florida
- Sylvester Comprehensive Cancer Center/ UMHC - Miami
Nebraska
- Oncology Hematology West P.C. dba Nebraska Cancer Specialists - Omaha
New Jersey
- Atlantic Health System / Morristown Medical Center - Morristown
Virginia
- Inova Dwight and Martha Schar Cancer Institute - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2021-05-19 |
| Est. Completion | 2025-11-24 |
| Phase | Phase 2 |
What the finished NCT04526899 record still lists
NCT04526899 is an interventional study that assigns participants to a tested intervention. The registered 184 participants enrollment target is mid-sized for trials with a published cap, above the 134-participant average among 24 other Unresectable Melanoma trials with a reported enrollment target (37% higher).
The record links to 3 conditions, with Unresectable Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Cemiplimab is the first listed.
NCT04526899 names 20 study sites across 7 states, led by Other, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT04526899 about?
NCT04526899 is a clinical study titled "A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment". This is an open-label, randomized, multi-site, Phase II, interventional trial designed to evaluate the efficacy, tolerability, and safety of BNT111 + cemiplimab in anti-programmed death protein 1 (PD-1)/anti-programmed death ligand 1 (PD-L1)-refractory/relapsed patients with unresectable Stage III o...
What is the current status of trial NCT04526899?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 184 participants. The study started on 2021-05-19. Estimated completion is 2025-11-24.
What conditions does trial NCT04526899 study?
This clinical trial studies the following conditions: Unresectable Melanoma, Melanoma Stage IV, Melanoma Stage III.
What interventions are being tested in trial NCT04526899?
The interventions under investigation include: Cemiplimab (BIOLOGICAL), BNT111 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04526899?
This trial is sponsored by BioNTech SE, which has 53 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04526899 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Nebraska, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unresectable Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04526899's enrollment target sits among peer trials
184 6th of 24 higher than 19 of 24 other Unresectable Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Unresectable Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
RECRUITING · Phase 2
-
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
RECRUITING · Phase 2
-
Prebiotic Food-enriched Diet (PreFED) to Enhance the Microbiome and Response to First-line Immunotherapy in Unresectable Melanoma
RECRUITING · Phase 2
-
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
RECRUITING · Phase 2
-
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03903510 · 184 participants · NA
Virtual Reality During Pediatric Cast Removal
- NCT04020510 · 184 participants · Phase 4
Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder
- NCT04135846 · 184 participants · Phase 2
Alpha-1 Blockade for Alcohol Use Disorder (AUD)
- NCT04396873 · 184 participants · Phase 1
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI